Antibody–Drug Conjugate to Treat Meningiomas

Kai Chen,Yingnan Si,Jianfa Ou,Jia-Shiung Guan,Seulhee Kim,Patrick Ernst,Ya Zhang,Lufang Zhou,Xiaosi Han,Xiaoguang Liu,Xiaoguang (Margaret) Liu

DOI: https://doi.org/10.3390/ph14050427

IF: 4.6

2021-05-02

Pharmaceuticals

Abstract:Meningiomas are primary tumors of the central nervous system with high recurrence. It has been reported that somatostatin receptor 2 (SSTR2) is highly expressed in most meningiomas, but there is no effective targeted therapy approved to control meningiomas. This study aimed to develop and evaluate an anti-SSTR2 antibody–drug conjugate (ADC) to target and treat meningiomas. The meningioma targeting, circulation stability, toxicity, and anti-tumor efficacy of SSTR2 ADC were evaluated using cell lines and/or an intracranial xenograft mouse model. The flow cytometry analysis showed that the anti-SSTR2 mAb had a high binding rate of >98% to meningioma CH157-MN cells but a low binding rate of <5% to the normal arachnoidal AC07 cells. The In Vivo Imaging System (IVIS) imaging demonstrated that the Cy5.5-labeled ADC targeted and accumulated in meningioma xenograft but not in normal organs. The pharmacokinetics study and histological analysis confirmed the stability and minimal toxicity. In vitro anti-cancer cytotoxicity indicated a high potency of ADC with an IC50 value of <10 nM. In vivo anti-tumor efficacy showed that the anti-SSTR2 ADC with doses of 8 and 16 mg/kg body weight effectively inhibited tumor growth. This study demonstrated that the anti-SSTR2 ADC can target meningioma and reduce the tumor growth.

pharmacology & pharmacy,chemistry, medicinal

What problem does this paper attempt to address?

The paper aims to develop and evaluate an anti-SSTR2 antibody-drug conjugate (ADC) for meningioma to address the current lack of effective targeted therapies for controlling meningioma. Specifically, the researchers focus on:

1. **High recurrence rate of meningioma**: Meningioma is one of the most common primary tumors in the central nervous system, especially malignant meningioma, which has a high recurrence rate and mortality rate.

2. **High expression of SSTR2**: Studies have shown that most meningiomas highly express somatostatin receptor 2 (SSTR2), but there are currently no approved effective targeted therapies to control these tumors.

3. **Development of new targeted therapies**: Researchers hope to develop an anti-SSTR2 ADC that can specifically target and treat meningioma, thereby reducing tumor growth and recurrence.

To achieve this goal, the researchers conducted the following work:

- **Construction of ADC**: An anti-SSTR2 monoclonal antibody was prepared and conjugated with the FDA-approved potent payload DM1 through a sulfo-SMCC linker to form the ADC.

- **In vitro and in vivo experiments**: The targeting specificity, circulation stability, toxicity, and anti-tumor effects of the ADC were evaluated through cell line experiments and intracranial xenograft mouse models.

- **Pharmacokinetic studies**: Through pharmacokinetic (PK) studies, the optimal dose and dosing interval of the ADC were determined.

- **Toxicity evaluation**: The potential toxicity of the ADC was assessed in non-meningioma-bearing mice, and the results showed that the ADC had no significant toxic effects on major organs.

Overall, the study demonstrated that the anti-SSTR2 ADC can effectively target meningioma and inhibit its growth, with low toxicity and good safety.